Antimicrobial Activity of the Serum before and after Vaccination with EpiVacCorona

Abstract

We evaluated the effect of vaccination with anti-COVID-19 vaccine EpiVacCorona on serum antimicrobial activity, formation of specific IgG antibodies, and expression of some antimicrobial peptides. Antimicrobial activity of the serum from 55 volunteers towards S. aureus cells was measured spectrophotometrically; IgG-antibodies against SARS-CoV-2 antigen were assayed by ELISA; expression of genes encoding antimicrobial peptides LL37, HBD1, and HBD2 was evaluated by PCR with reverse transcription. Total antimicrobial serum activity and activity of its low-molecular-weight fraction containing antimicrobial peptides demonstrated an inverse correlation. Both activities after vaccination increased in case of low initial values, but decreased in case of high initial values. The vector of change of specific IgG antibodies to coronavirus inversely correlated with the vector of change of activity of antimicrobial peptide fraction. The expression of genes of antimicrobial peptides LL37, HBD1, and HBD2 looked like normal distribution depending on activities of the antimicrobial peptides in the corresponding sera.

COVID-19 Vaccines: Where Did We Stand at the End of 2023?

“…These findings were confirmed in a phase III trial in Paraguay [ 46 ]. The EpiVarCorona (EVCV) vaccine is based on synthesized peptide antigens and immunogens from the SARS-CoV-2 S protein, which elicited immune responses in various animal models and prevented pneumonia in hamsters and non-human primates [ 119 ]. Moreover, good safety and prevention of COVID-19 was observed in phase I/II [ 47 ].…”